Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii56–64
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Lung cancer: the diagnosis and treatment of lung cancer. London: National Institute for Health and Care Excellence, 2011
   Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283–9
   PubMed Web of Science ®Google Scholar
• Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41:81–92
   PubMed Web of Science ®Google Scholar
• Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010;5:260–74
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii27–39
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005
   Google Scholar
• Barletta G, Genova C, Rijavec E, et al. Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2014;15:1585–99
   PubMed Web of Science ®Google Scholar
• Bennouna J, Havel L, Krzakowski M, et al. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an international randomized phase II study (NAVotrial 01). Clin Lung Cancer 2014;15:258–65
   PubMed Web of Science ®Google Scholar
• Grossi F, Buffoni L, Favaretto A, et al. Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: vinorelbine orale e cisplatino o pemetrexed e cisplatino seguiti da mantenimento rispettivamente con vinorelbine orale e pemetrexed nel trattamento del carcinoma polmonare non a piccole cellule non squamoso (NS-NSCLC) in stadio avanzato. PharmacoEcon Ital Res Artic 2014;16:19
   Google Scholar
• Favaretto A, Ciuffreda L, Nicolini M. Oral vinorelbine (NVBo) plus cisplatin (CDDP) versus pemetrexed (PEM) plus CDDP followed by maintenance with single agent NVBo or PEM as first-line treatment of patients (pts) with advanced nonsquamous non small cell lung cancer (NS-NSCLC): a cost minimization analysis from the Italian National Health System (NHS) perspective. Eur J Cancer 2013;49:329
   PubMed Web of Science ®Google Scholar
• Bennouna J. Prospective randomised phase II trial of oral vinorelbine and cisplatin (P) or pemetrexed and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: final results. J Clin Oncol 2013;31(Suppl):8043
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47
   PubMed Web of Science ®Google Scholar
• KELA. Medicinal Products Database. 2014. Available at: https://easiointi.kela.fi/laakekys_app/LaakekysApplication?kieli=en. [Last accessed 23 April 2014]
   Google Scholar
• Caisse nationale de l’assurance maladie des travailleurs salariés. Table National de codage de Biologie. 2014. Available at: http://www.codage.ext.cnamts.fr/. [Last accessed 28 October 2014]
   Google Scholar
• Lauer-Fischer GmbH. Webapo InfoSystem 2014. Available at: http://www2.lauer-fischer.de/produkte/lauer-taxe/webapo-infosystem-english/. [Last accessed 24 April 2014]
   Google Scholar
• Companies THAoP. Bulletin of Medicines for Human Use (New Original) 02/11/2014. 2014. Available at: https://www.sfee.gr//wp-content/uploads/2014/07/NEA_PRWTOTYPA_1102014.xlsx. [Last accessed 24 April 2014]
   Google Scholar
• Norwegian Medicines Agency. Legemiddelsøk. 2014. [Last accessed 16 April 2014]
   Google Scholar
• Ministry of Health of the Slovak Republic. Drug List. 2014
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Botplusweb. 2014. Available at: https://botplusweb.portalfarma.com/botplus.aspx. [Last accessed 23 October 2014]
   Google Scholar
• Gesundheit BF. Spezialitätenliste. 2014. Available at: http://www.spezialitaetenliste.ch/. [Last accessed 24 October 2014]
   Google Scholar
• Pharmaceutical Press, British Medical Journal Group. British National Formulary. 2014. Available at: https://www.medicinescomplete.com/mc/bnf/current/index.htm. [Last accessed 3 April 2014]
   Google Scholar
• Gesundheit Österreich Beratungsgesellschaft mbH. Pharma price information (PPI). In: Austrian Drug Prices. Vienna, 2014
   Google Scholar
• Všeobecná zdravotní pojištovna Ceské republiky. Republiky VzpČ. Ciselnik: 960. 2014
   Google Scholar
• Statens Serum Institut. Takstsystem – Vejledning. In: Sundhedsdokumentation SfNSoF, ed. 3. 2014
   Google Scholar
• Legemiddelinnkjopssamarbeid. Drug Database. 2014. Available at: http://www.lisnorway.no/sider/artikler.asp?mal=forside&type=aktuelt&ant=4&meny=Forside&undermeny=false&meny=Forside&undermeny=false
   Google Scholar
• Bundesministerium für Gesundheit Leistungsorientierte Krankenanstaltenfinanzierung. Vienna, 2014
   Google Scholar
• Statens Serum Institut. Sundhedsøkonomi og DRG. 2014. Available at: http://www.ssi.dk/Sundhedsdataogit/Sundhedsokonomi%20og%20-finansiering/Sundhedsoekonomi%20og%20DRG.aspx [Last accessed 24 February 2014]
   Google Scholar
• Kansaneläkelaitos - The Social Insurance Institution of Finland. Toimenpiteet. In: Finnish DRG rates. 2014
   Google Scholar
• SwissDRG. Fallpauschalenkatalog SwissDRG 3.02014
   Google Scholar
• Monitor. UK National Tariff. 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/300551/Annex_5A_National_Prices.xlsx
   Google Scholar
• L’hospitalisation Atdlis. Les fichiers des tarifs de GHS, GHT sont disponibles. 2014
   Google Scholar
• System IG-IftHR. G-DRG-System 2014 Fallpauschalen-Katalog. 2014. Available at: http://www.g-drg.de/cms/inek_site_de/layout/set/standard/G-DRG-System_2014/Fallpauschalen-Katalog
   Google Scholar
• Helsedirektoratet. Kostnadsvektene for Innsatsstyrt finansiering 2014. 2014. Available at: http://helsedirektoratet.no/finansiering/drg/kostnadsvekter/Documents/Kostnadsvekter%202014%20-%20dokumentasjon%20av%20KV-arbeidet%202013.pdf
   Google Scholar
• Government of the Slovak Republic. Catalogue of medical services and Government Regulation no. 223 form 4 May 2005 amending Regulation of the Government of the Slovak Republic no. 776/20042014
   Google Scholar
• Ministry of Health of the Greek Republic. Goverment Gazette. 2011
   Google Scholar
• Le Lay K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007;8:145–51
   PubMed Web of Science ®Google Scholar